Actively Recruiting
Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid
Led by CHU de Reims · Updated on 2024-06-27
140
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bullous pemphigoid (BP) is the most frequent autoimmune skin disease and mainly affects elderly individuals. BP classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense itches. However, BP is characterized by a large spectrum of clinical presentations allowing to distinguish between typical (with blisters) and atypical forms (non bullous, mucosal damage). High potency topical steroids and systemic steroids are the current first line intention treatments. While very efficient, these therapies are non-targeted and cause numerous side-effects, especially in these elderly patients that are the most affected. Furthermore, around 30% of BP patients will relapse during the first year of treatment when corticotherapy is decreased or stopped. The investigators and others have highlighted the presence of Il-17 family belonging-inflammatory cytokines in BP patients. Their functions in the amplification of the inflammatory response and in the mechanisms of relapse have to be precisely determined in order to develop innovative therapeutic approaches and to move forwards precision medicine.
CONDITIONS
Official Title
Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with Bullous Pemphigoid showing at least three of four established clinical criteria
- Presence of subepidermal blister on skin biopsy
- Deposits of IgG and/or C3 in a linear pattern along the epidermal basement membrane by direct immunofluorescence
- Patient agrees to participate in the study
- Patient is affiliated with the French Healthcare System
You will not qualify if you...
- Unable to provide written informed consent before inclusion
- Diagnosis of pemphigoid gestationis
- Relapse of Bullous Pemphigoid
- Received local superpotent corticotherapy within 14 days before inclusion
- Received systemic corticosteroid treatment within 28 days before inclusion
- Anemia with hemoglobin less than 10 g/dL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chu Reims
Reims, France, 51092
Actively Recruiting
Research Team
M
Manuelle VIGUIER, Pr.
CONTACT
S
Sébastien LE JAN, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here